Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives more

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots

DHR enhances patient safety by deploying robots to destroy germs
and bacteria that can cause infections

EDINBURG, Texas--(BUSINESS WIRE)--As hospitals across the nation look for new and innovative ways to battle deadly pathogens and kill multi-drug resistant organisms that can cause Hospital Acquired Infections,Doctors Hospital at Renaissance Health System (DHR) has taken a leap into the future with the installation of seven Germ-Zapping Robots™ that destroy hard-to-kill bugs in hard-to-clean places. DHR is the first hospital in the Rio Grande Valley to tap into a technology that uses pulsed xenon ultraviolet (UV) light to quickly destroy bacteria, viruses, mold and other pathogens.

From doctors and staff to patients and visitors, hundreds of people enter a hospital daily, unknowingly escorting a host of contaminants and germs on their person. Enterovirus D-68,C.diff, MRSA, VRE – an alphabet soup of deadly pathogens lurk in the very place people go to get healthy. In demonstration of its commitment to keep patients safe, DHR has taken an important step into the future to zap dangerous superbugs and stop the spread of healthcare associated infections (HAIs).

The seven Xenex robots at DHR use Full Spectrum™ pulsed xenon UV light to quickly destroy harmful bacteria, viruses, fungi and bacterial spores. The portable disinfection system is effective against even the most dangerous pathogens, including Clostridium difficile (C.diff),norovirus, influenza, Ebola and methicillin-resistant Staphylococcus aureus, better known as MRSA.

“We aim to do everything possible to provide a clean environment at DHR to reduce the risk of hospital acquired infections,” said Dr. Carlos Cardenas, DHR Chief Administrative Officer. “We have long been recognized as South Texas’ leader in medical technology and highly specialized care, so it’s only fitting that we should employ the same level of technological innovation when it comes to removing the pathogens that can cause infections.”

Cardenas continues, “One hospital acquired infection is one too many, so we are excited to begin using the Xenex system to help us achieve our goal of zero infections. This investment is important and underscores our commitment to patient care and the communities we serve. Not only will these robots provide a cleaner environment for patients, but it also ensures an optimal environment for visitors and our employees.”

The Xenex Full Spectrum UV room disinfection system works by pulsing xenon, an inert gas, at a high intensity in a xenon ultraviolet flashlamp. This produces intense ultraviolet C (UVC) light which penetrates the cell walls of microorganisms, including bacteria, viruses, mold, fungus and spores. Their DNA is fused, rendering them unable to reproduce or mutate, effectively killing them on surfaces without contact or chemicals.

The portable Xenex system can disinfect a typical patient or procedure room in five minute cycles without warm-up or cool-down times. It can be used in any department and in any unit within a healthcare facility, including isolation rooms, operating rooms, general patient care rooms, contact precaution areas, emergency rooms, bathrooms and public spaces.

The Xenex Germ-Zapping Robot has been tested and proven using independent lab verification on the most common, dangerous and difficult-to-treat microorganisms. Most importantly, the Xenex system has been credited by health care facilities across the U.S. for helping them reduce their infection rates significantly. Xenex Germ-Zapping Robots are backed by published, peer-reviewed patient outcome studies. The devices are mercury-free, which is beneficial for the hospital and the local environment. More than 350 hospitals, Veterans Affairs (VA) and DOD facilities nationwide are using the system with the purpose of reducing rates of infection and saving costs. And it’s safe. Because the light is extremely intense, the machine operates on its own once it’s set up in a room. For enhanced safety, a sign placed outside the door warns people not to enter, and a motion sensor automatically shuts off the machine if someone should enter.

With germ-zapping robots on the EVS team, DHR is proud of its commitment to patient safety. Explains Director of Infection Control, Mary Lou Love, MSN, RN, “We already have a strong infection prevention program in place. This robot is helping us be more effective at eradicating the superbugs that pose a threat to patients, their families and our staff.”

Xenex Disinfection Services
Xenex's patented Full Spectrum pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex’s mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include Malin Corporation, Battery Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit www.Xenex.com.

Doctors Hospital at Renaissance Health System
From general acute care services to individually-tailored wellness and preventative health programs, at Doctors Hospital at Renaissance (DHR) over 700 physicians and more than 1,500 nurses dedicate themselves to offering a full continuum of care in over 70 different sub-specialties. DHR is a 513-bed physician-owned health system that offers some of the most comprehensive medical care on the U.S. Southern Border. For more information, please call (956) DOCTORS (362-8677) or visit our website at www.dhr-rgv.com. For more information on Doctors Hospital at Renaissance’s clinical certifications, please contact Irene Ochoa, Director of Clinical Certification.

Contacts
DHR
Reannon Ramos, 956-362-7358
rea.ramos@dhr-rgv.com
or
Xenex
Melinda Hart, 210-240-4669
melinda.hart@xenex.com

Source: http://www.businesswire.com/news/ back

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial more

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more